|Articles|January 28, 2015
Merck and Novo Nordisk Join TransCelerate
TransCelerate BioPharma Inc. today announced two new members, Merck & Co. Inc., and Novo Nordisk, to the biopharmaceutical non-profit organization.
Advertisement
TransCelerate BioPharma announced two new members, Merck & Co. Inc., and Novo Nordisk, to the biopharmaceutical non-profit organization, bringing the total number of members to 23. In addition, TransCelerate has appointed Briggs Morrison, MD, Executive Vice President, Global Medicines Development at AstraZeneca, to the position of Chair of the Board of Directors. Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
2
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
3
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
4
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
5